Ann: SIRFLOX ASCO Abstract Released, page-32

Hi yes, I've never doubted SRX's efficacy in the liver.. and I doubt anyone in the medical community has. That's why I bought in the stock at $3.
I don't see today's release as "news"... it's a nice shock absorber from the last release and confirmation of previous trial results with a much larger group of patient data. Scientifically it's very much welcome.

PFS is a desired outcome in any trial, for good reasons...
I'd like to see how the company will leverage these results and move beyond salvage therapy, as they should.

Lastly, I'd suggest that the goal of SRX is not turn liver cancer into a controllable disease, but rather reduce the progression into a resectable state. i.e., this has the potential to be a curative therapy for certain patients.
Welcome news indeed for them.